{"component": "definition", "props": {"groups": [{"snippet": "is defined in Section 5.5.2(b).", "snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [3, 21]}], "samples": [{"hash": "jpnZcbP2zYu", "uri": "/contracts/jpnZcbP2zYu#useful", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 31.8446269678, "published": true}, {"hash": "ggnshgntmlA", "uri": "/contracts/ggnshgntmlA#useful", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.749486653, "published": true}, {"hash": "lgwM84kDb46", "uri": "/contracts/lgwM84kDb46#useful", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.7385352498, "published": true}], "size": 10, "hash": "46fafda2fa79877fd8214c6985bcc4bf", "id": 1}, {"snippet": "heat shall mean heat generated to satisfy an economical justifiable demand for heat, for heating or cooling purposes;", "snippet_links": [], "samples": [{"hash": "lCu0Zjdcw39", "uri": "https://ec.europa.eu/transparency/regdoc/rep/1/2016/EN/COM-2016-767-2-EN-ANNEX-1-PART-1.PDF", "label": "ec.europa.eu", "score": 6.6550308008, "published": false}, {"hash": "fMrSfzYKyQN", "uri": "https://www.astrid-online.it/static/upload/dire/directive_renewableannexes.pdf", "label": "www.astrid-online.it", "score": 6.4565366188, "published": false}, {"hash": "fdkvD04956I", "uri": "https://news.wko.at/news/oesterreich/%5B602%5D-Beilage2_RED_Review_Annexes.pdf", "label": "news.wko.at", "score": 6.4565366188, "published": false}], "size": 8, "hash": "a82bd1591a6e491298971eefad7ffacc", "id": 2}, {"snippet": "heat shall mean heat generated to satisfy an economical justifiable demand for heat;", "snippet_links": [], "samples": [{"hash": "iLBSkg5wGDk", "uri": "https://images.politico.eu/wp-content/uploads/2016/11/RED-II-ANNEXES.pdf", "label": "images.politico.eu", "score": 8.4113620808, "published": false}, {"hash": "lCu0Zjdcw39", "uri": "https://ec.europa.eu/transparency/regdoc/rep/1/2016/EN/COM-2016-767-2-EN-ANNEX-1-PART-1.PDF", "label": "ec.europa.eu", "score": 6.6550308008, "published": false}, {"hash": "fMrSfzYKyQN", "uri": "https://www.astrid-online.it/static/upload/dire/directive_renewableannexes.pdf", "label": "www.astrid-online.it", "score": 6.4565366188, "published": false}], "size": 5, "hash": "3d30b024f1ec559ba6fc7ef496defad3", "id": 3}, {"snippet": "means that Allogene has determined in its discretion that use of such Third Party\u2019s Patent Right would enhance the commercial potential of such Allogene Licensed Product. For the avoidance of doubt, the Parties agree and acknowledge that this Section 5.2.2(b) will not apply with respect to royalties payable by Allogene to any Third Party under any agreement in existence as of June 17, 2014. Neither Party will intentionally negotiate with a Third Party an exclusive license that excludes sublicense rights to the other Party, in the event such Third Party rights are necessary, as determined by the negotiating Party, to Develop and Commercialize Allogene Licensed Products and Cellectis Products in connection with this Agreement in the Field.", "snippet_links": [{"key": "in-its-discretion", "type": "clause", "offset": [35, 52]}, {"key": "patent-right", "type": "clause", "offset": [84, 96]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [171, 197]}, {"key": "the-parties-agree", "type": "clause", "offset": [199, 216]}, {"key": "with-respect-to", "type": "clause", "offset": [275, 290]}, {"key": "royalties-payable", "type": "clause", "offset": [291, 308]}, {"key": "in-existence", "type": "definition", "offset": [360, 372]}, {"key": "neither-party", "type": "clause", "offset": [394, 407]}, {"key": "a-third-party", "type": "clause", "offset": [442, 455]}, {"key": "exclusive-license", "type": "clause", "offset": [459, 476]}, {"key": "sublicense-rights", "type": "clause", "offset": [491, 508]}, {"key": "other-party", "type": "clause", "offset": [516, 527]}, {"key": "in-the-event", "type": "clause", "offset": [529, 541]}, {"key": "third-party-rights", "type": "clause", "offset": [547, 565]}, {"key": "negotiating-party", "type": "definition", "offset": [602, 619]}, {"key": "to-develop", "type": "definition", "offset": [621, 631]}, {"key": "licensed-products", "type": "definition", "offset": [659, 676]}, {"key": "in-connection-with", "type": "clause", "offset": [700, 718]}, {"key": "this-agreement", "type": "clause", "offset": [719, 733]}, {"key": "in-the-field", "type": "clause", "offset": [734, 746]}], "samples": [{"hash": "ib3o6qlxVJZ", "uri": "/contracts/ib3o6qlxVJZ#useful", "label": "License Agreement (Allogene Therapeutics, Inc.)", "score": 30.3442847365, "published": true}, {"hash": "hWAQrrYmJk", "uri": "/contracts/hWAQrrYmJk#useful", "label": "License Agreement (Cellectis S.A.)", "score": 30.311430527, "published": true}, {"hash": "gjqpYGfA6Qf", "uri": "/contracts/gjqpYGfA6Qf#useful", "label": "License Agreement (Cellectis S.A.)", "score": 30.1909650924, "published": true}], "size": 3, "hash": "ce3ab9080a7b1c7bfe1fb56f65df1663", "id": 4}, {"snippet": "Life\" of non-expendable personal property shall mean that useful service life as based upon the United States Department of Treasury, Internal Revenue Service, policies on depreciation for tax purposes, unless the Contractor or Subcontractor documents in writing some different period that the County agrees to in writing.", "snippet_links": [{"key": "expendable-personal-property", "type": "clause", "offset": [13, 41]}, {"key": "service-life", "type": "definition", "offset": [65, 77]}, {"key": "the-united-states", "type": "definition", "offset": [92, 109]}, {"key": "department-of-treasury", "type": "definition", "offset": [110, 132]}, {"key": "internal-revenue-service", "type": "definition", "offset": [134, 158]}, {"key": "tax-purposes", "type": "definition", "offset": [189, 201]}, {"key": "contractor-or-subcontractor", "type": "definition", "offset": [214, 241]}, {"key": "in-writing", "type": "definition", "offset": [252, 262]}, {"key": "the-county-agrees-to", "type": "clause", "offset": [290, 310]}], "samples": [{"hash": "fErHf2NFkLJ", "uri": "/contracts/fErHf2NFkLJ#useful", "label": "Senior Center Services Agreement", "score": 26.0376454483, "published": true}, {"hash": "5VrcJ6iXRWA", "uri": "/contracts/5VrcJ6iXRWA#useful", "label": "Contract Agreement", "score": 23.1026694045, "published": true}, {"hash": "aVA7edWYUUN", "uri": "/contracts/aVA7edWYUUN#useful", "label": "Basic Agreement", "score": 22.9712525667, "published": true}], "size": 3, "hash": "dd0a788ef5acbb6d5c63016525c67624", "id": 5}, {"snippet": "means necessary or useful in the Manufacture of the Licensed Peptide or Product or the Development of the Licensed Peptide or Product or Commercialization of the Product in the Field. Subject matter created by or on behalf of Riptide in the course of the performance of activities under Section 5.4 shall be deemed Useful.", "snippet_links": [{"key": "development-of-the", "type": "clause", "offset": [87, 105]}, {"key": "commercialization-of-the-product", "type": "clause", "offset": [137, 169]}, {"key": "in-the-field", "type": "clause", "offset": [170, 182]}, {"key": "subject-matter", "type": "definition", "offset": [184, 198]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [207, 225]}, {"key": "in-the-course-of", "type": "definition", "offset": [234, 250]}, {"key": "activities-under", "type": "clause", "offset": [270, 286]}, {"key": "section-54", "type": "clause", "offset": [287, 298]}], "samples": [{"hash": "hKcc7E0411Q", "uri": "/contracts/hKcc7E0411Q#useful", "label": "Collaboration & License Agreement (Aurinia Pharmaceuticals Inc.)", "score": 32.6249144422, "published": true}, {"hash": "9z6Ua8rn7Tc", "uri": "https://www.auriniapharma.com/investors-and-media/sec-filings/all-sec-filings/content/0001628280-21-017175/0001628280-21-017175.pdf", "label": "www.auriniapharma.com", "score": 16.4504894241, "published": false}, {"hash": "bzFx6cblRQd", "uri": "https://ir.auriniapharma.com/all-sec-filings/content/0001628280-21-017175/0001628280-21-017175.pdf", "label": "ir.auriniapharma.com", "score": 10.8124572211, "published": false}], "size": 3, "hash": "c7190c67923714915c9dd947babc836d", "id": 6}, {"snippet": "means that Pfizer has determined that such Third Party\u2019s Patent Right would reasonably enhance the commercial sales potential of such Licensed Product, provided that Third Party Patent Rights covering the Manufacture or formulation of such Licensed Product shall only be considered Useful to the extent they cover the form of such Licensed Product as it exists at the time that the Additional Third Party License is executed. For the avoidance of doubt, the Parties agree and acknowledge that this Section 5.5.2(b) shall not apply with respect to royalties payable by Pfizer to any Third Party under any agreement in existence as of the Effective Date.", "snippet_links": [{"key": "commercial-sales", "type": "clause", "offset": [99, 115]}, {"key": "licensed-product", "type": "clause", "offset": [134, 150]}, {"key": "provided-that", "type": "clause", "offset": [152, 165]}, {"key": "third-party-patent-rights", "type": "definition", "offset": [166, 191]}, {"key": "to-the-extent", "type": "clause", "offset": [289, 302]}, {"key": "form-of", "type": "definition", "offset": [318, 325]}, {"key": "at-the-time", "type": "clause", "offset": [361, 372]}, {"key": "additional-third-party-license", "type": "definition", "offset": [382, 412]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [426, 452]}, {"key": "the-parties-agree", "type": "clause", "offset": [454, 471]}, {"key": "with-respect-to", "type": "clause", "offset": [531, 546]}, {"key": "royalties-payable-by-pfizer", "type": "clause", "offset": [547, 574]}, {"key": "in-existence", "type": "definition", "offset": [614, 626]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [627, 651]}], "samples": [{"hash": "jpnZcbP2zYu", "uri": "/contracts/jpnZcbP2zYu#useful", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 31.8446269678, "published": true}, {"hash": "ggnshgntmlA", "uri": "/contracts/ggnshgntmlA#useful", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.749486653, "published": true}], "size": 2, "hash": "075fe339417a907b8e4c6bd2520c1723", "id": 7}, {"snippet": "means that Pfizer has determined in its discretion that use of such Third Party\u2019s Patent Right would enhance the commercial potential of such Pfizer Licensed Product. For the avoidance of doubt, the Parties agree and acknowledge that this Section 5.4.2(b) will not apply with respect to royalties payable by Pfizer to any Third Party under any agreement in existence as of the Effective Date. Neither Party will intentionally negotiate with a Third Party an exclusive license that excludes sublicense rights to the other Party, in the event such Third Party rights are necessary, as determined by the negotiating Party, to Develop and Commercialize Licensed Pfizer Products and Cellectis Products in connection with the Research Program in the Field.", "snippet_links": [{"key": "in-its-discretion", "type": "clause", "offset": [33, 50]}, {"key": "patent-right", "type": "clause", "offset": [82, 94]}, {"key": "licensed-product", "type": "clause", "offset": [149, 165]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [167, 193]}, {"key": "the-parties-agree", "type": "clause", "offset": [195, 212]}, {"key": "with-respect-to", "type": "clause", "offset": [271, 286]}, {"key": "royalties-payable-by-pfizer", "type": "clause", "offset": [287, 314]}, {"key": "in-existence", "type": "definition", "offset": [354, 366]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [367, 391]}, {"key": "neither-party", "type": "clause", "offset": [393, 406]}, {"key": "a-third-party", "type": "clause", "offset": [441, 454]}, {"key": "exclusive-license", "type": "clause", "offset": [458, 475]}, {"key": "sublicense-rights", "type": "clause", "offset": [490, 507]}, {"key": "other-party", "type": "clause", "offset": [515, 526]}, {"key": "in-the-event", "type": "clause", "offset": [528, 540]}, {"key": "third-party-rights", "type": "clause", "offset": [546, 564]}, {"key": "negotiating-party", "type": "definition", "offset": [601, 618]}, {"key": "to-develop", "type": "definition", "offset": [620, 630]}, {"key": "in-connection-with", "type": "clause", "offset": [697, 715]}, {"key": "the-research-program", "type": "clause", "offset": [716, 736]}, {"key": "in-the-field", "type": "clause", "offset": [737, 749]}], "samples": [{"hash": "f1Qu2VgZEVk", "uri": "/contracts/f1Qu2VgZEVk#useful", "label": "Research Collaboration and License Agreement (Allogene Therapeutics, Inc.)", "score": 29.7008898015, "published": true}, {"hash": "fxyLkOKdvfM", "uri": "/contracts/fxyLkOKdvfM#useful", "label": "Research Collaboration and License Agreement (Cellectis S.A.)", "score": 26.1909650924, "published": true}], "size": 2, "hash": "465e05d1ac189e929b965b012f309888", "id": 8}, {"snippet": "means operable, in the sense that the product or process achieves the result that the inventor claims it will. One could not patent a perpetual motion machine, for example, even if its design was highly novel, unless the patent applicant could prove that the machine actually worked (a dubious prospect, at least according to current scientific understanding). At one time patent applicants had to demonstrate some sort of beneficial usefulness for the invention, but that is no longer the case. Even if the invention is so expensive and inefficient that no rational person would ever make or use it, the invention is still eligible for a patent as long as it is capable of performing the function ascribed to it, and meets the other requirements of patentability, such as novelty and nonobviousness.", "snippet_links": [{"key": "the-product", "type": "clause", "offset": [34, 45]}, {"key": "the-inventor", "type": "clause", "offset": [82, 94]}, {"key": "for-example", "type": "clause", "offset": [160, 171]}, {"key": "the-patent", "type": "definition", "offset": [217, 227]}, {"key": "according-to", "type": "definition", "offset": [313, 325]}, {"key": "the-invention", "type": "definition", "offset": [449, 462]}, {"key": "the-case", "type": "definition", "offset": [486, 494]}, {"key": "capable-of", "type": "definition", "offset": [663, 673]}, {"key": "the-function", "type": "clause", "offset": [685, 697]}, {"key": "other-requirements", "type": "clause", "offset": [728, 746]}], "samples": [{"hash": "j4ovI6qLzch", "uri": "http://www.eolss.net/sample-chapters/c04/e6-31-02-03.pdf", "label": "www.eolss.net", "score": 8.4948665298, "published": false}, {"hash": "1gurJ4q9JXA", "uri": "https://www.eolss.net/Sample-Chapters/C04/E6-31-02-03.pdf", "label": "www.eolss.net", "score": 8.3169062286, "published": false}], "size": 2, "hash": "32ec623c206490c57d6d4f8aebd4c675", "id": 9}, {"snippet": "means that Pfizer has determined that such Third Party\u2019s Patent Right would reasonably enhance the potential, including by reducing cost or complexity of Manufacture, of such Licensed Product.", "snippet_links": [{"key": "third-party", "type": "clause", "offset": [43, 54]}, {"key": "patent-right", "type": "clause", "offset": [57, 69]}, {"key": "licensed-product", "type": "clause", "offset": [175, 191]}], "samples": [{"hash": "boFAVcOl38", "uri": "/contracts/boFAVcOl38#useful", "label": "Research Collaboration and License Agreement (BioNTech SE)", "score": 30.6865160849, "published": true}, {"hash": "81kBKZ1QJ5j", "uri": "/contracts/81kBKZ1QJ5j#useful", "label": "Research Collaboration and License Agreement (BioNTech SE)", "score": 30.5906913073, "published": true}], "size": 2, "hash": "47037fdd21249674d77bbdeed551a89c", "id": 10}], "next_curs": "ClMSTWoVc35sYXdpbnNpZGVyY29udHJhY3Rzci8LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIPdXNlZnVsIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "is defined in Section 5.5.2(b).", "title": "Useful", "size": 45, "id": "useful", "examples": ["Grantee will follow the procedures in the American Hospital Association\u2019s (AHA) \u201cEstimated <strong>Useful</strong> Lives of Depreciable Hospital Assets\u201d in disposing, at any time during or after the Contract term, of equipment purchased with the System Agency funds, except when federal or state statutory requirements supersede or when the equipment requires licensure or registration by the state, or when the acquisition price of the equipment is equal to or greater than $5,000.", "All cost reimbursement Grantees must follow the American Hospital Association\u2019s (AHA) \u201cEstimated <strong>Useful</strong> Lives of Depreciable Hospital Assets\u201d for equipment disposition purposes, except when federal or statutory requirements supersede.", "A DBE performs a Commercially <strong>Useful</strong> Function (CUF) when it is responsible for execution of the work of the Agreement and is carrying out its responsibilities by actually performing, managing, and supervising the work involved.", "A DBE performs a Commercially <strong>Useful</strong> Function (CUF) when it is responsible for execution of the work of the contract and is carrying out its responsibilities by actually performing, managing, and supervising the work involved.", "If the Prime CONSULTANT is, a DBE certified firm they must comply with the Commercial <strong>Useful</strong> Function (CUF) regulation outlined in the AGENCY\u2019s \u201cDBE Program Participation Plan\u201d and perform a minimum of 30% of the total amount of this AGREEMENT.", "Except as provided in MCC 2-92-525(b)(2), only compliance plans utilizing MBE and WBE firms that meet BOTH the Commercially <strong>Useful</strong> Function and Area of Specialty requirements will be counted toward the Contract Specific Goals.", "Only expenditures to firms that perform a Commercially <strong>Useful</strong> Function as defined above may count toward the Contract Specific Goals.", "If the Prime CONSULTANT is a DBE certified firm they must comply with the Commercial <strong>Useful</strong> Function (CUF) regulation outlined in the AGENCY\u2019s \u201cDBE Program Participation Plan\u201d and perform a minimum of 30% of the total amount of this AGREEMENT.", "Replacement costs of Project Conservation Facilities shall be treated as either Capital Costs or as minimum operation, maintenance, power, and replacement costs, as determined by the State considering the Economic <strong>Useful</strong> Life of the asset being replaced and other relevant factors.", "Replacement costs of Project Transportation Facilities shall be treated as either Capital Costs or as minimum operation, maintenance, power and replacement costs, as determined by the State considering the Economic <strong>Useful</strong> Life of the asset being replaced and other relevant factors."], "related": [["cannabis-business", "Cannabis business", "Cannabis business"], ["developmentally-appropriate", "Developmentally appropriate", "Developmentally appropriate"], ["intellectual-property", "Intellectual Property", "Intellectual Property"], ["uses", "Uses", "Uses"], ["develop", "Develop", "Develop"]], "related_snippets": [], "updated": "2025-07-06T21:56:50+00:00"}, "json": true, "cursor": ""}}